🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

25 recruiting trials

for Gaucher Disease

Parkinson's Disease in Type 1 Gaucher Disease NCT07886879n/a1 site📍 New York Icahn School of Medicine at Mount Sinai PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's NCT06151002n/a1 site📍 London University College London Hospitals Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC NCT04528355n/a1 site📍 Pittsburgh Paul Szabolcs · Tests: data collection A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease NCT06818838Phase 1, Phase 23 sites📍 Guangzhou📍 Taiyuan📍 Tianjin Lingyi Biotech Co., Ltd. · Tests: LY-M001 PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) NCT04532047Phase 11 site📍 San Francisco University of California, San Francisco · Tests: Aldurazyme (laronidase) Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease NCT05843552n/a1 site📍 Minneapolis University of Minnesota · Tests: no intervention GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma NCT05992532n/a23 sites📍 Vitoria-Gasteiz📍 Almería📍 Palma de Mallorca Fundación Española de Hematología y Hemoterapía Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma NCT03721068Phase 12 sites📍 Atlanta📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine A Long-term Follow-up Study of Gaucher Disease NCT03190837n/a1 site📍 Durham Duke University Gaucher Disease Outcome Survey (GOS) NCT03291223n/a1 site📍 Lexington Shire A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I NCT06162338NA1 site📍 Hanzhou He Huang · Tests: LY-M001 Injection Institutional Registry of Rare Diseases NCT06573723n/a1 site📍 Buenos Aires Hospital Italiano de Buenos Aires Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease NCT02437396n/a1 site📍 Minneapolis University of Minnesota Registry of Patients Diagnosed With Lysosomal Storage Diseases NCT05619900n/a1 site📍 San Francisco University of California, San Francisco · Tests: There is no intervention Longitudinal Study of Neurodegenerative Disorders NCT03333200n/a1 site📍 Pittsburgh University of Pittsburgh · Tests: Palliative Care, Hematopoetic Stem Cell Transplantation A Gaucher Disease Gene Therapy Trial With FLT201 NCT07223944Phase 332 sites📍 Los Angeles📍 Los Angeles📍 San Francisco Spur Therapeutics · Tests: FLT201 Gaucherite - A Study to Stratify Gaucher Disease NCT03240653n/a8 sites📍 Birmingham📍 Birmingham📍 Cambridge Cambridge University Hospitals NHS Foundation Trust · Tests: Stratified response to Enzyme Therapy Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders NCT00029965n/a1 site📍 Bethesda National Human Genome Research Institute (NHGRI) Advancing Integrated Therapies for Gaucher Disease NCT07758816n/a1 site📍 New Haven Yale University Prodromal Parkinsonian Features in GBA1 Mutation Carriers NCT05253560n/a1 site📍 Jerusalem Shaare Zedek Medical Center · Tests: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease. An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease NCT06272149EARLY Phase 11 site📍 Shanghai Xinhua Hospital, Shanghai Jiao Tong University School of Me… · Tests: VGN-R08b MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3) NCT05586243n/a1 site📍 Minneapolis University of Minnesota · Tests: No intervention Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry NCT00358943n/a317 sites📍 Phoenix📍 Tucson📍 Little Rock Genzyme, a Sanofi Company World Data on Ambroxol for Patients With GD and GBA Related PD NCT04388969n/a3 sites📍 Jerusalem📍 Jerusalem📍 Jerusalem Shaare Zedek Medical Center
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy